Clonal V alpha 12.1+ T cell expansions in the peripheral blood of rheumatoid arthritis patients by unknown
Clonal Vctl2.1 + T  Cell Expansions in the Peripheral 
Blood of Rheumatoid Arthritis Patients 
By Harout  DerSimonian,*  Masahiko  Sugita,*  David  N.  Glass,~ 
Agnes  L.  Maier,*  Michael  E.  Weinblatt,*  Thierry  R~me, g 
and Michael  B.  Brenner* 
From the  *Department of Rheumatology  and Immunology,  Brigham  and Women's Hospital, 
Harvard Medical School, Boston, Massachusetts, 02115; the *Division of Rheumatology, 
Children's Hospital Medical Center, Cincinnati, Ohio  45229; and $INSERM  U 291, 34197 
Montpellier Cedex 5, France 
Summary 
Rheumatoid arthritis (R.A) represents a heterogenous disease characterized by chronic polyarthritis. 
Most patients with adult RA inherit HLA-DR4 or -DR1 major histocompatibility complex 
(MHC) genes. While the molecular basis for this genetic predisposition is unknown, the major 
function of these MHC-encoded molecules is to present peptides to T lymphocytes. It is hypothesized 
that an endogenous or environmental antigen initiates a MHC-restricted immune  response mediated 
by T  lymphocytes, which is followed by a chronic inflammatory reaction involving many cell 
types.  In chronic RA,  previous or  ongoing antigenic activation might result in detectable 
skewing of the peripheral ot/~ T cell receptor (TCR) repertoire.  Here we demonstrate a marked 
expansion of Vc~12.1-bearing  CD8 +  T  cells  in  the  peripheral blood  (mean,  22%;  range, 
10-43%) of >15%  of RA patients. A major proportion of these patients shared  HLA-DQ2 
in addition to the expected high frequency DR1 and DR4 alleles. Detailed molecular analysis 
in three of the RA patients with elevated Vot12.1 + T  cells identified repeated TCR. ol chain 
sequences consistent with clonal Vot12.1 + ,CD8 + T cell expansion. In addition to shared TCR 
Vo~12.1 germline gene usage among unrelated subjects, a conserved Jot motif was also detected. 
Together, these results suggest an antigen-driven mechanism ofT cell expansion in these patients 
and may offer a new approach in examining specific antigens that stimulate T  cells in RA. 
heumatoid arthritis  (RA) 1 is  an  autoimmune disease 
that manifests itself in patients with chronic inflam- 
mation, synovial proliferation, and progressive joint damage 
(1). Several lines of evidence point to a role for T  cells in 
the pathogenesis of RA. These include a genetic predisposi- 
tion associated with MHC class II genes,  whose products 
function to present antigens to T  cells (2-4),  the presence 
of activated T cells in inflamed synovial tissues and periph- 
eral blood (5), and the therapeutic utility of treatments that 
at least partially inhibit T  cell function (6,  7). 
The major population of T  lymphocytes that recognize 
antigen in the context of self-MHC molecules bear the TCR 
oe/~ heterodimer in association with the CD3 complex (8). 
Each chain is divided into a V  region that recognizes the 
Ag/MHC complex and a C region that anchors the mole- 
cule to the cell surface. The TCR o~/~ chains are assembled 
by somatic recombination of discontinuous germline gene 
1 Abbreviations used in this paper: EAE, experimental allergic encephalo- 
myelitis; iPCR, inverse polymerase chain reaction; RA, rheumatoid arthritis. 
segments during T  cell  development. Polymerization of 
template-independent N  region and template-dependent P 
nucleotide insertions at the junctions, D~ usage, the impre- 
cise joining of the germline gene segments (selected from 
a large pool), and the combinatorial association of TCR o~/~ 
polypeptides help to generate an extensive diversity in the 
TCR ol/~ repertoire (9). 
During T cell development, only a small fraction of the 
thymocytes are able to emigrate into the periphery as mature 
CD4 + or CD8 § T  cells. Negative selection events  delete 
self-reactive TCR oe/~-bearing T cells (10, 11), while posi- 
tive selection events rescue single-positive CD4 + or CD8 + 
T  cells (12-14).  Positive  selection yields mature CD4 + T 
cells that are predominantly self-MHC class II restricted or 
CD8 + T cells that are predominantly self-MHC class I re- 
stricted (15). The binding of antigen peptides to MHC mol- 
ecules has provided a molecular explanation for the corecog- 
nition  of Ag/MHC  by  the  TCR  ol/B  (16). TCR  gene 
sequences and hypothetical modeling based on Ig molecules 
suggest that the TCR V regions (especiaUy  those regions cot- 
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cule, while the highly diverse V-(D)-Jjunctional region (cor- 
responding to CDR3) contacts antigenic peptides bound to 
the MHC molecule (9,  17). 
There are strong correlations between TCK V gene usage 
and T  cell antigen recognition specificity in animal studies 
(18).  Striking T  cell repertoire correlations also have been 
obtained for experimental allergic encephalomyelitis (EAE), 
an experimental model of autoimmune disease in mice and 
rats (19). It has been shown, for instance, that induction and 
maintenance of the disease is dependent on myelin basic pro- 
tein-spedfic T cell clones that utilize a restricted pool of Voe, 
Jc~, and VB gene segments. Since, antigenic specificity in RA 
is not known, it has been difftcult to establish T cell clones 
from RA patients to study antigen recognition and TCR 
V gene usage. The identification of a restricted T cell popu- 
lation based on TCK gene usage in RA might be useful in 
identifying  the relevant autoantigens and offer new therapeutic 
approaches  for this disease. 
Here, we used a Voe12.1-specific 6D6 mAb (20) in cell sur- 
face staining to identify a subset (17%) of RA patients that 
showed a striking elevation in the number of Vo~12.1 +  ,CD8 + 
T  cells in PBL. Analysis of the Vol12.1 + ,CD8 + T  cells in 
three unrelated individuals by nucleotide sequencing revealed 
evidence  for clonal T  cell expansion. Most of the patients 
with TCR Vo~12.1-elevated CD8 + T  cells also shared the 
HLA-DQ2 phenotype. These results provide evidence sug- 
gesting that antigen-driven expansion of T  cells may be a 
component of chronic RA. 
Materials  and Methods 
Immunofluorescence and Flow Cytometry.  Flow cytometric anal- 
yses were performed using directly conjugated antibodies. Two- 
color analyses  on PBL were carried out as described  previously  using 
a FACScan  |  (Becton Dickinson & Co., Mountain View, CA) (20). 
PBMC was isolated  from fresh  blood of  donors using Ficoll-Hypaque 
and stained with FITC-conjugated anti-CD4 (OKT4) or anti-CD8 
(OKT8) versus PE-conjugated anti-Vow12.1 (6D6) mAbs. Viable 
cells were analyzed by gating on the propidium iodide-excluding 
lymphocytes.  The following formula was used to calculate the per- 
centage value for Vcr  expression on CD4 + and CD8 + subsets: 
percent  V,~12.1+,CD4  +  (or  Vc~12.1§  +)  cells  =  100x 
[Vex12.1 + cells costained with anti-CD4 (or anti-CD8)/percent of 
total CD4 + (or CD8 §  T cells]. 
Tissue Staining.  Samples  of synovial  membranes were obtained 
as discarded tissue from surgery, snap-frozen  immediately in liquid 
nitrogen, and stored at -80~  4-/~m-thick  sections were cut and 
fixed in alcohol-acetone for 10 min at 4~  and stored at  -20~ 
Sections were rehydrated in PBS for 10 min, and two-color fluores- 
cence staining was performed as described previously (21). Dual- 
color fluorescence  staining was performed using 6D6-biotin (anti- 
V,~12.1) mAb and developed with tricolor-coupled streptavidin 
(Caltag, Paris, France). Tricolor is a two-stage PE-Texas red fluores- 
cent dye excited at 488 nm, with an emission peak at 650 nm. 
As a second step, samples  were stained with commercially  available 
FITC-coupled anti-CD4 or anti-CD8 mAb (Immunotech, Mar- 
seilles). Slides were mounted with a drop of Fluoprep medium and 
sealed. Confocal microscope observations were carried out using 
an Optiphot fluorescence microscope (Nikon Inc., Instr. Group, 
Melville, NY) equipped with a confocal head (MKC600; Bio-Rad 
Laboratories, Richmond, CA) possessing a 488-nm argon laser and 
two photomultipliers  detecting mirror-reflected  light (green fluores- 
cence) and the pass-through  light (red fluorescence).  The two signals 
were computerized with the Comos software (Bio-Rad Laborato- 
ties), and a photograph was taken with a black-and-white camera. 
After merging both slides in a 256 optimized color bitmap, a pho- 
tograph was taken with a color screen photographic device. CD8 + 
cells are seen in green and Va12.1 + cells are seen in red. The 
double-stained Vc~12.1  §  § T cells are seen in yellow. 
Polymerase Chain Reaction.  Subsets  ofT cells  were enriched  using 
anti-CD4, anti-CDS, or anti-Vc~12.1 mAbs with magnetic beads 
(Dynal, Inc., Great Neck, NY). For example, CDS-entiched T cells 
were isolated by depletion of CD4 § T cells using anti-CD4 mAb 
and magnetic beads, while CD4-entiched T cells were isolated by 
depletion of CD8 + T  cell using anti-CD8  mAb and magnetic 
beads. Each of these depleted populations was further subjected 
to  enrichment  using  anti-Vc~12.1 mAb  and  magnetic  beads. 
Purification of KNA from these cells was carried out according 
to Chomczynski  and Sacchi  (22). cDNA for the direct PCR method 
of amplification  was synthesized in a reverse transcription reaction 
using AMV reverse transcriptase, 5 #g of total KNA, and 500 ng 
of oligo-(dT)12-1s primer before amplification with Vcd2.1- and 
Col-specific primer  combination.  For inverse (i)PCK,  double- 
stranded cDNA was synthesized  from total KNA (2 #g) and circula- 
rized using T4 DNA ligase (23). Using a pair of C0x or C3 primers 
oriented in an outward direction from one another, '~700-bp PCK 
products were generated corresponding to the full-length TCK c~ 
or 3  chain transcripts (24). PCR primers were Vcc12.1-specific, 
5'~TCGACT'IGCCAGCCTGTTGAGGC~AG; Cc~-specific, 
5  'GGGAA~TACAC~_K~AGC~TCAGG; Cc~-forward, 
5'GGGTCGACGACCTCATGTCTAGCACAGT;  Cc~-inverse, 
5'-  GCATGCGGCCGCCCTGCTATGCTGTGTGTCT;  C3-for- 
ward, 5'-GGGTCGACACACAGCGACCTCGGGTGGG;  CO-in- 
verse, 5'-GCATGCGGCCGCCATGGTCAAGAGAAAGGA. 
Cloning and Sequencing.  PCK products were cloned into M13 
plasmids and sequenced by the dideoxynucleotide chain termina- 
tion method using the modified  T7 polymerase  (Sequenase; United 
States Biochem. Corp., Cleveland,  OH). The sequencing products 
were resolved  on polyacrylamide  gels, and autoradiography  was car- 
tied out according to standard methods. 
Serologic HLA Typing.  HLA class I and class II antigens were 
typed serologically  by the Brigham and Women's Hospital Tissue 
Typing Laboratory (Boston, MA). Serotyping of HLA-A, -B, -C, 
-DR, and -DQ was performed using standard microcytotoxicity 
techniques. 
Results 
VcrI2.1-bearing CD8 + T Cells Are Elevated in Patients with 
Reel.  The relative percentage  of TCR Vo~12.1 on CD4 + or 
CD8 + T cell subsets in the peripheral  blood of RA patients 
was  assessed by two-color fluorescence  staining and flow 
cytometry using the Vc~12.1-specific mAb 6D6 (20).  Anal- 
ysis of both RA patient (n  =  46) and healthy control (n  = 
68)  PBL showed similar frequencies  of Vo~12.1 expression 
by CD4 + T  cells  (mean,  2.6%;  range,  1-4%).  Likewise, 
one group  of 38  patients contained percentages  of TCR 
Vcr  § T  cells in the CD8*  subset (mean, 3.6%; range, 
1-7%) that were similar to those found in healthy controls. 
However, a second group of RA patients had elevated per- 
centages of Vo~12.1  + T  cells in the CD8 + subset that ex- 
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Figure  1.  Expansion  of Vc~12.1  + T  cells in RA.  Two-color  immu- 
nofluorescence analysis of TCR Vot12.1 § expression on CD4 § and CD8 + 
T cell subsets was carried  out on PBMC from 68 normal controls  (left) 
and 46 RA patients (right),  and the results of each individual were con- 
nected by a line. The mean ages (and ranges) for Vc~12.1-normal  and Vot12.1- 
elevated individuals were 58.8  _+  13 (29-79)  and 56.4  _+  10 (40-69)  yr 
of age, respectively.  The mean and  proportion of the  total  CD4 + and 
CD8 + T  cells in the VoL12,1-elevated and Vc~12.1-normal groups were 
similar. 2 of 8 (25%) in the Vod2.1-elevated group and 10 out of 38 (26%) 
in the Vod2.1-normal  group were males. 
ceeded  7.4%,  2  SD above the mean of healthy individuals 
(Fig.  1).  Vot12.1 + T  cell expansions in the CD8 + popula- 
tion were found in 8 of 46 (17%) RA patients and were ab- 
sent in all 68 healthy controls (Fisher's exact test, p  =  0.00047). 
Among these eight patients  Vot12.1  was expressed on 43, 
29, 27, 26, 22, 20, 12, and 10% (mean, 22%) of the CD8 + 
T cells, respectively (Fig.  1, V~2.1-elevated).  The elevations 
of Vot12.1 §  T  cells was a stable phenomenon since similar 
values were obtained over a 24-mo period in several of the 
subjects (data  not  shown). 
Elevated  VcrI2.1 +  T  Cells  Are  Represented  as  Clonal  or 
Oligoclonal Expansions.  The precise molecular structure of 
the  Vod2.1 +  TCR  cz  chains  was  determined  by  cDNA 
cloning and sequencing from the CD8 + cells purified from 
three  Vc~12.1-elevated  patients.  PCR  products  containing 
Vcd2.1 rearrangements were generated by direct amplification 
using Vot12.1- and Cot-specific oligonucleotide primers. For 
each patient  a distinct  Vcd2.1-containing  sequence corre- 
sponding to a functional TCR oL chain transcript was repeated 
extensively (Fig. 2 A).  For example, in patient 1, in whom 
43%  of the  CD8 +  T  cells  were  VoL12.1 +,  all  15  cDNA 
TCR. ol sequences obtained were identical.  Similarly,  9  of 
16 identical sequences were obtained in patient 2, in whom 
29%  of the CD8 + T  cells were Vcz12.1 + .  Analysis  of pa- 
tient  3,  in  whom  22%  of CD8 +  T  cells  were  Vot12.1 +, 
A 
v~  /  JU  : 
Patient  1 : 
Vul2.1/J~A1 
patient  2 : 
vu12.1/JuAI2 
Val2.1/J~A24 
VU12.1/J~4 
VUI2.1/JUA20 
VUI2.  I/J~AI5 
Val2.1/JUP 
V~I2.1/JuAI6 
V(z12.1/J~A9 
Patient  3 ￿9 
VUI2.  I/J~A6 
VU12.1/J~A6 
VU12.1/JUAI4 
VUI2.  I/JUAI4 
VUI2.1/J~A26 
VUI2.1/JUA 
VUI2.  i/J~AI0 
VUI2.1  /  J~/q 
# of RePeated Clones 
3'  V~I2.1  J~ Seouence  Direct  Inverse  (PCR) 
CALS  DGYG(}NFVFGPGTRLSVLPY  15/15  9/9 
CALS 
CALSS 
CAL 
CALSE 
CALBE 
CALS 
CAL 
CALSEA 
DYOGGSEKLVFOKGMKLTVI~  9/16  ND 
GAYNTNAOKSTFGDGTTLTVI~PN  1/16  NEt 
TQTNAOKBTFODGTTLTVKPN  1/16  ND 
VGGANNLFFGTGTRLTVIPY  1/16  ND 
PGSIqlCEg~FGAGTRLTVKPN  1/16  ND 
GIDDKIIFGKGTRLHILPN  1/16  ND 
LRSGGTNKLIFGAGTRLAVHPY  1/16  hl) 
WGGSQGNLIFGKGTKLSVKPN  1/16  ND 
CAL  RGGGADGLTFGKGTHLII0j~  16/24  21/27 
CALSE  PYSGGGADGLTFGKGTHLIIQ~  3/24  5/27 
CALS  GLDSGNTPLVFGKGTRLSVZAN  1/24  0/27 
CALSEA  QDSGNTPLVFGKGTRLSVIAN  0/24  1/27 
CALSE  PNTGRRALTFGSGTRI~VQPN  1/24  0/27 
CALSEA  YSSASKIIFGSGTRLSIRPN  1/24  0/27 
CAL  RVGKSISNFGNEKLTFGTGTRLTIIPN  1/24  0/27 
CALSE  OANDI'KLSFGAGTTVTVRAN  1/24  0/27 
t  1 
I. 
.: .-~:,."J.-  I- 
vp8  ,. 
B 
VB/DB/JB  : 
Patient  1 : 
5.1/1.1/2.7 
Patient  3 : 
8.1/1.1/1.2 
17  /1.1/1.1 
17  /2.1/2.6 
22  /1.1/2.1 
22  /1.1/2.7 
2.1/2.1/2.3 
3.1/2.1/2.3 
3.3/2.1/2.1 
15  /1.1/2.5 
3'  v~  DS/J8 Seuuence 
CABS  SKQGLMHEQYFGPGTRLTVT 
of Repeated Clones 
Inverse PCR 
18118 
CABS  LATPAYGYTFGSGTRLTVV  12/20 
CASS  WTGNTEAFFGQGTRLTVV  1/20 
C.ASS  TPRBGANVLTFGAGSRLTVL  1/20 
CABS  G(~0FFGPGTRLTVL  1/20 
CABS  SDVSFTIQYFGPGTRLTVT  1/20 
CSA  RVPGLAGGTTNTDTQYFGPGTRLTVL  1/20 
CABS  ATGTSGSGGVDTQYFGPGTRLTVL  1/20 
CABS  WTL~QFFGPGTRLTVL  1/20 
CATS  SLG(]GREETQYFGPGTRLLVL  1/20 
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Figure  2.  Repeated  TCR ot and  B chain  se- 
quences  in Vcz12.1+,CD8 + T  cells. (A) Amino 
acid sequences were deduced from nucleic acid se- 
quencing of eDNA clones generated by direct PCR 
or iPCR amplification.  TCR Vot12.1 sequences 
were obtained by direct PCR using Vex12.1- and 
Cot-specific oligonucleotide primers on highly en- 
riched CD8 + T cells and by iPCR using highly 
enriched  Vot12.1+,CD8 + T  cells. (B) TCR V~8 
sequences found in Vc~12.1+,CD8 + T cells of pa- 
tients 1 and 3 were generated by iPCR. (C) Two- 
color FACS  |  analysis with anti-Vc~12.1 (6D6) and 
anti-V•8  (16(38;29) mAbs was performed on CD4- 
depleted  PBL from patient 3. identified two distinct repeated sequences; of these, one se- 
quence accounted for 16 of 24 clones, and the second repeated 
sequence was identified in 4 of 24 clones. Although the  junc- 
tional sequences were different in the two repeated Vot12.1 
sequences in patient 3, both used the same Jot gene segment, 
JotA6 (Fig. 2 A). 
These results were confirmed using the ilK2K methodology, 
which utilizes circularized DNA and a pair of ot chain C re- 
gion oligonucleotide primers oriented away from one another 
(23, 24). TCK Vot-containing transcripts were cloned and 
sequenced from Vot12.t +  ,CD8 + T cells purified from PBL. 
This analysis of patients  1 and 3 revealed the same repeated 
TCK ot chain sequences  that were found with the direct PCR 
amplifications (Fig. 2 A). A similar analysis of healthy sub- 
jects revealed diverse TCR ot chain sequences with no occur- 
rence of repeated sequences (data not shown).  Among the 
repeated sequences found in the three patients examined, the 
Vot12.1 was rearranged to distinct Jot gene segments: JotA1, 
JotA12, and Jo~A6 in patients  1, 2, and 3, respectively. In- 
terestingly,  all of these Jot gene segments encode the same 
amino acid dipeptide sequence (pro-tyr) at their 3' ends (Fig. 
2 A). Notably, only 6 of the 80 known Jot genes encode this 
dipeptide sequence, and may constitute a family of function- 
ally related Jot gene segments (25-28; DerSimonian, H., and 
M. B. Brenner, manuscript in preparation). 
We also analyzed  the TCR/3 chain transcripts in the purified 
VOt12.1+,CD8 +  T  cells using  the  iPCR  methodology. 
Hence, all potential VB  transcripts  in Va12.1+,CD8 + T 
cells from patients I and 3 were cloned and sequenced (Fig. 
2 B).  All 18 V/~ cDNA clones in the purified  Vot12.1  +, 
CD8 + T cells were identical in patient 1. Moreover, 12 of 
20 eDNA clones from patient 3 were identical but differed 
from the repeated V/3 sequence identified in patient 1. Since 
the repeated sequence in patient 3 predicted a VB8-encoded 
TCR, cell surface  coexpression  of  Votl2.1 and VB8 gene prod- 
ucts on CD8 + T cells was demonstrated by flow cytometry 
using the Vot12.1-specific  mAb (6D6) and the VB8-specific 
mAb (16G8; 29), confirming the molecular cloning results 
(Fig.  2 C). 
Expanded VoH2.1 + T Cells Carry the "Memory" Phenotype. 
Staining of Vot12.1 + T cells with mAb specific to various 
activation antigens was carried out in two-color flow cytom- 
etry analysis as shown for Votl2.1-elevated patient 1 (Fig. 
3 A). Such analyses  for patients 1-3 are summarized in histo- 
A 
(CD8  + T Cells)  (Ve~IZI+CD8  + T Ceils) 
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Figure  3.  Vot12.1  + T cells activation phenotype. Two-color staining of Vo~12.1  + T cells from fresh PBMC of one V~x12.1-elevated patient is dis- 
played by dot plot analysis. (,4) PBL from patient 1 shows costaining with FITC-coupled anti-Vod2.1 mAb on the x-axis vs. PE-coupled  anti-CD45RO 
(top righ 0 (UCHL1; 3% anti-lb21kc~ (middle left) (B1.49.9; 31), anti-Ib2RB (middk right) (TU27; 32), anti-VLA-1 (bottom left) (TS2/7; 33), or anti-HLA-DR 
(bottom right) (LB3.1; 34) mAb staining on the y-axis. (B) Bar graph representation of percent positive for the two-color staining using the anti-IL-2R~, 
anti-IL-21~, anti-HLA-DR, anti-VLA-1, and anti-CD45RO mAbs for CD8 + T cells in healthy donors 1-3 (left) and for Vt~12.1  +  ,CD8 + T cells in 
patients 1-3 (right). 
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peripheral Vot12.1+,CD8 + T  cells expressed  the memory 
marker CD45RO +. In addition, 10-30% of these cells ex- 
pressed detectable levels of VLA-1, an antigen expressed on 
long-term or chronically activated T cells (35, 36), HLA-DR 
antigens, and IL-2R 13 chain. These results are consistent with 
previous antigen activation and reveal ongoing activation by 
a fraction of the Vot12.1+,CD8 + peripheral T  cells in the 
Vot12.1-elevated RA patients. They stand in contrast to the 
lower percentages of CD8 § T cells from healthy subjects ex- 
pressing these activation markers (Fig.  3 B). Only percen- 
tages of IL-2R ~  chain-bearing cells are similar in normal 
CD8 + T  cells from healthy donors and Vot12.1 +,CD8 + T 
cells from the RA patients. 
Distribution  of Voe12.1 +,  CD8 + T  Cells  in the Synovium. 
The primary finding in this study is the expansion ofa Vot12.1- 
bearing CD8 § T cell population in the peripheral blood of 
a subset of RA patients. Two of these Vc~12.1-elevated pa- 
tients received a medically indicated joint operation during 
the course of study allowing analysis of their synovial tissues. 
Frozen sections were stained for two-color confocal fluores- 
cence microscopy with anti-Vot12.1 mAb 6D6 (red) and anti- 
CD8 or anti-CD4 mAb (green). Each two-color fluorescent 
slide was screened for at least 50 cells containing at least five 
lymphocyte-rich areas (at 240 x). The black-and-white bitmap 
pictures  from  each  photomultiplier were  simultaneously 
recorded and merged after recoloring. An example of such 
an evaluation of double-positive  (Voe12.1  +,CD8 +) cell stain- 
ing is shown as the merged product of the CD8 + (top left) 
and Vc~12.1  + (top right) by scanning of the same field (Fig. 
4).  Each  double-stained cell  is  seen  in yellow (Vot12.1 +, 
CDS+),  composed of green  (CD8 +)  and  red  (Vot12.1 +) 
color overlap. Synovial membrane staining of the two Vot12.1- 
elevated patients (nos.  2 and 4) revealed that 8.5 and 10% 
of CD8 + T cells in their synovial tissue expressed Vot12.1 +, 
compared with 29 and 27% of their peripheral blood CD8 * 
T cells, respectively (Table 1). Thus, the Vce12.1  +  ,CD8 + T 
cells appear to represent a substantial number of the synovial 
tissue CD8 + T  cells, but not as large a fraction as of the 
peripheral CD8 + T cells. Two Vcd2.1-normal patients (nos. 
25 and 46) were also examined and they expressed 3.6 and 
6.2%  Vo~12.1+,CD8 + cells in their synovial  tissues  com- 
pared with 4.9 and 5.3% in their peripheral blood samples, 
respectively. Too few synovial tissue analyses from (periph- 
eral) Vot12.1-evaluated donors were made to allow a statistical 
assessment. 
Patients with Expanded  Voel2.1 + T  Cells Share HLA.DQ2. 
The MHC alleles present among the RA patients were ana- 
lyzed and compared in both the Vot12.1-elevated  and Vot12.1- 
normal groups. As expected, DR1 and DR4 alleles  were prom- 
inently represented in both groups. Interestingly,  the propor- 
tion of HLA-DQ2 (which is in strong linkage disequilibrium 
with DR3 and DR7) was substantially higher among the 
Vot12.1-elevated versus the Vot12.1-normal group (Fisher's 
exact test, p  =  0.002),  as it was found in 7 of 8 (88%) (Table 
2) compared with 10 of 38 (26%) patients, respectively. This 
difference was similar to that of Vot12.1-elevated  patients when 
Figure 4.  Analysis  of Vot12.1 § ,CD8 + T cells in synovial tissue by con- 
focal microscopy.  Double-fluorescence  staining (see Materials and Methods) 
of RA synovial membrane with FITC-coupled anti-CD8 mAb (top left) 
and PE-coupled anti-Vot12.1 (6D6) mAb (top  right)  are  shown in black 
and white. Fluorescence of the same field is recorded at the two emission 
wavelengths in a confocal microscope. Computerized 256 optimized color 
side merge of black and white bitmaps is shown where  single-positive 
CD8 + (green) or Vot12.1  + (red) cells are visualized (bottom).  Double- 
stained (Vc~12.1*,CD8  +) cells are seen in yellow. An example of a double- 
stained cell is marked with the arrow  (x 240). 
compared to the expected positivity of 33%  in an outbred 
North  American  population  (X  2  5.05,  P  <0.025)  (37). 
While the significance of increased DQ2 frequency for the 
risk of developing RA is unknown, the donal (or oligoclonal) 
expansions of Vc~12.1+,CD8 +  T  cells appear  to be more 
likely in DQ2-positive individuals. Patients in the Vo~12.1- 
elevated group did not differ clinically, however,  from the 
Vot12.1-normal group with respect to age, sex, duration of 
disease, rheumatoid factor positivity, erythrocyte sedimenta- 
tion rates, or arthritis activity measured  by number of painful 
joints and global assessments. 
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and CD8 Subsets 
Table  2,  Patients  with Expanded  Vcrl2.1 + T  Cells 
in  the  CD8  Subset 
Patients 
2  4  25  46 
CD8 § T cells 
expressing 
KA patient  Vc~12.1"  HLA class I  HLA class II 
Peripheral blood 
Vcd2.1/CD4  2.8%*  2.6%  1.5%  1.8% 
Vcd2.1/CD8  29%  27%  4.9%  5.3% 
CD4/CD8  63:38  61:41  71:29  48:52 
Synovial tissue 
Vcd2.1/CD4  3.7%  6.7%  0.0%  0.3% 
Vcd2.1/CD8  8.5%  10.0%  3.6%  6.2% 
CD4/CD8  55:45  58:42  44:56  61:39 
* Percentage  of Vc~12.1 + T cells in the CD4 + or CD8 + T cell subset 
was calculated according to the formula in Materials and Methods: per- 
cent of Vcd2.1+,CD4 §  (or Vot12.1+,CDS+)/percent  of total CD4 + 
(or CD8 +) T  cells. 
Discussion 
In this study, staining with Vc~12.1-specific  mAb and flow 
cytometry identified a subset of RA patients  with elevated 
numbers of Vo~12.1  +  ,CD8 + T cells in the peripheral blood. 
The molecular analysis  revealed  that these T ceUs  were donaUy 
(patients 1 and 2) or oligodonaUy (patient 3) expanded, evi- 
denced by TCKs encoded by repeated Vod2.1 gene sequences. 
The marked expansion in Vc~12.1  +  ,CD8 + T cells reported 
here was  detected because fluorescence staining  with  the 
Vcx12.1-specific mAb could be readily performed on a large 
number of subjects with CD4 + and CD8 + T cells analyzed 
separately. Such screening approaches may be necessary to 
detect a particular TCK usage phenomenon when it occurs 
in only a subset of patients.  The Vod2.1-elevated patients 
described here may correspond to an immunologically defined 
subset even though clinically these patients were similar to 
the Vcx12.1-normal group. This study, examining the TCK 
repertoire in RA, differs from other analyses  in several  aspects 
(38). Other studies have predominantly focused on the VB 
repertoire (39-41), performed analyses on the synovial fluid 
or tissue and on mixtures of both CD4 + and CD8 + T cells 
(24, 39-44),  and generally have examined only a few donors 
(24, 41-43). Neverthdess, previous examples  of repeated TCKs 
VB14 and VB17 (as well as VB2, Vfl3, and Vfl13.2 sequences) 
in synovial fluid or tissue have suggested that donal T cell 
expansion maybe an important aspect of this disease (40, 41). 
Several examples of restricted Vow, Ja,  and VB usage in 
murine T calls have been reported that characterize a partic- 
ular T call response to known foreign antigens, for example, 
Vex11 and Vfl3 in response to cytochrome c (45-47),  Vol2 
and Vfll in response to ~, repressor cI protein (48), Vow4 and 
Vfll0 in response to lymphocytic  choriomeningitis virus gly- 
coprotein (49, 50), and Vo~2.3 or Vex4 rearranged to the same 
Joe gene segment, together with Vf18.2 in the myelin basic 
% 
1  43*  A__, B44, 
A32, B60, Cw3 
2  29  A1, B8 
A2, B__, 
3  22  A2, B52 
All, B48 
4  27  A2, B35, Cw4 
All, B57, Cw3 
5  26  A30, B14, 
A23, B13, 
6  20  A23, B27, Cw2 
A24, B42, 
7  12  A2, B7, 
A29, B44, 
8  9  A30, B7, 
All, B40, 
DP,7, DQ2 
DR4,  DQ3 
DR3,  DQ2 
DR4 DQ3 
DR3  DQ2 
DR10  DQ_ 
DR1  DQ1 
DR2 
DR7  DQ2 
DR1  DQ1 
DK4  DQ2* 
DP.5  DQ__ 
DR3  DQ2 
DK7  DQ4 
DK3  DQ2 
DK10  DQ1 
Typing for HLA class I and II was carried out serologicaUy using stan- 
dard  microcytotoxicity techniques. 
* mAb 6D6  surface staining. 
* Confirmed by PCK sequence-specific probe analysis. 
protein-induced EAE animal model of autoimmune disease 
(51-53). Thus, a strong antigen-driven activation may cause 
proliferation of T cell clones that utilize specific  Vot, Jc~, and 
V~  sequences  that  ultimately  dominate  as  donal  (or 
oligoclonal) populations of circulating T cells in patients with 
chronic RA. While the mechanism responsible for the clonal 
Vo~12.1 + T cell expansion in this subset of RA patients is 
not known, the restricted Vot/Jot usage in unrelated patients 
and the CD45RO  expression by the elevated Vot12.1 + T 
cells  provide  support  for  an  antigen-driven  activation 
mechanism. 
The additional occurrence of the P-Y residues in the Jc~- 
encoded sequences of these TCKs is another interesting fea- 
ture of their structure. Preliminary TCK modeling suggests 
this segment of the Jo~ is near the switch or hinge region 
that joins the V and C domains. Residues at this site would 
be unlikely to participate in antigen-MHC recognition, but 
are predicted to be solvent exposed and might interact with 
an accessory cellular ligand or impose an effect on TCR c~ 
chain conformation if this region of the TCK is analogous 
to the counterpart region in Ig (A. K. Kees, personal com- 
munication, University of Bath,  UK). 
A relationship between HLA-DQ2 and the TCK Vod2.1 + 
clonal expansion can only be inferred  at present.  One hy- 
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or a closely linked gene might act to select for the individual 
done,  or alternatively HLA-DQ2 might  act as the restric- 
tion  element  in presenting  antigen  to Vod2.1 + T  cells  in 
the periphery. It is surprising that the expansion of a CD8 § 
T  cell subset would be associated with the expression of a 
MHC class II allele since CD8 + T  cells generally recognize 
peptide antigens presented by MHC class I molecules (15). 
However, a role for MHC class  II and HLA-DQ-encoded 
molecules in particular  in  the activation  and expansion  of 
CD8 +  T  cells  has  been  suggested  in  a  number  of  ex- 
perimental and clinical conditions where these cells function 
as regulatory or cytolytic lymphocytes (54-57). It is notable 
that the human antigen-specific T cell clones so far charac- 
terized show a bias for HLA-DQ restriction.  For example, 
CD8 + T  cell clones derived from blood or lesions  of pa- 
tients with lepromatous leprosy were restricted to HLA-DQ 
(54). Alternatively, peptides derived from HLA-DQ mole- 
cules may be relevant antigens presented by other HLA mol- 
ecules. For instance, it has been shown that HLA-B7-derived 
peptides can be presented by DR11.1 (58), that HLA-DR3- 
derived peptides can be presented by HLA-DPw3 (59), and 
in a cross-species system HLA-Cw3-derived peptides were 
presented  on murine  H-2K  a (60).  Further,  recent  peptide 
elution experiments  from human  and mouse MHC mole- 
cules have identified numerous peptide sequences encoded by 
other MHC alleles  (61,  62). 
Whether  the Vot12.1 + T  cell population or the antigen 
to which it responds are critical to the pathology of the rheu- 
matoid  disease  process  itself  remains  to  be  determined. 
Nevertheless, clonal expansions that  account for a mean of 
22% of the CD8 + T  ceils in the peripheral blood are such 
large populations numerically that it seems likely that they 
may have an important  functional impact. Since the expan- 
sion is in the CD8 + pool of peripheral blood T  cdls, these 
may be a regulatory T cell subset, rather than the predomi- 
nant proinflammatory T cell in the synovium. Defining this 
aberration in a subset of patients may have relevance to the 
diagnosis and treatment  of this disease.  These clonal T  cdl 
populations together with associated MHC molecules offer 
newly identified tools to examine specific T  cell antigens in 
this  autoimmune  disorder of unknown  etiology. 
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